Evidence map›Paper›PMID 38954982›Full record

ArticleBiochemical and biophysical research communications2024

A method for rapid and reliable quantification of VEGF-cell binding activity.

Prabuddha Waduge, Avinash Kaur, Wei Li

Abstract read
In one paragraph

Article in Biochemical and biophysical research communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Prabuddha WadugeCullen Eye Institute, Department of Ophthalmology, Baylor College of Medicine, Houston, TX, 77030, USA.
Avinash KaurCullen Eye Institute, Department of Ophthalmology, Baylor College of Medicine, Houston, TX, 77030, USA.
Wei LiCullen Eye Institute, Department of Ophthalmology, Baylor College of Medicine, Houston, TX, 77030, USA. Electronic address: wei.li4@bcm.edu.

Funding

VISION RESEARCH CENTERP30EY002520 · NEI · BAYLOR COLLEGE OF MEDICINE · PI Samuel M Wu · 1985 to 2026
$14.8M
A selective angiogenesis blocker to treat retinopathy of prematurityR24EY028764 · NEI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI LI, WEI · 2019 to 2023
$7.6M
A Diabetic Retinopathy-Associated Vascular Permeability FactorR01EY027749 · NEI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI LI, WEI · 2018 to 2022
$2.2M
Developing a novel disease-targeted anti-angiogenic therapy for CNVR21EY035421 · NEI · BAYLOR COLLEGE OF MEDICINE · PI LI, WEI · 2023 to 2023
$440k
A new drug entity for combination therapy of diabetic retinopathyR43EY032827 · NEI · EVERGLADES BIOPHARMA, LLC · PI LI, WEI, TIAN, HONG · 2021 to 2021
$257k
Anti-angiogenic gene therapy of ocular vascular diseasesR43EY031238 · NEI · EVERGLADES BIOPHARMA, LLC · PI LI, WEI, TIAN, HONG · 2020 to 2020
$225k
NEI NIH HHS P30 EY002520NEI NIH HHS R01 EY027749NEI NIH HHS R21 EY035421NEI NIH HHS R24 EY028764NEI NIH HHS R43 EY031238NEI NIH HHS R43 EY032827
6 · The paper itself

Abstract

Vascular endothelial growth factor (VEGF) is a pleiotropic growth factor that binds a broad spectrum of cell types and regulates diverse cellular processes, including angiogenesis, growth and survival. However, it is technically difficult to quantify VEGF-cell binding activity because of reversible nature of ligand-receptor interactions. Here we used T7 bacteriophage display to quantify and compare binding activity of three human VEGF-A (hVEGF) isoforms, including hVEGF111, 165 and 206. All three isoforms bound equally well to immobilized aflibercept, a decoy VEGF receptor. hVEGF111-Phage exhibited minimal binding to immobilized heparan sulfate, whereas hVEGF206-Phage and hVEGF165-Phage had the highest and intermediate binding to heparan, respectively. In vitro studies revealed that all three isoforms bound to human umbilical vein endothelial cells (HUVECs), HEK293 epithelial and SK-N-AS neuronal cells. hVEGF111-Phage has the lowest binding activity, while hVEGF206-Phage has the highest binding. hVEGF206-Phage was the most sensitive to detect VEGF-cell binding, albeit with the highest background binding to SK-N-AS cells. These results suggest that hVEGF206-Phage is the best-suited isoform to quantify VEGF-cell binding even though VEGF165 is the most biologically active. Furthermore, this study demonstrates the utility of T7 phage display as a platform for rapid and convenient ligand-cell binding quantification with pros and cons discussed.

Indexed as

Human Umbilical Vein Endothelial CellsProtein BindingVascular Endothelial Growth Factor ABacteriophage T7Cell Surface Display TechniquesHEK293 CellsHeparan SulfateHumansProtein IsoformsReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsafliberceptHeparan SulfateProtein IsoformsReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsVascular Endothelial Growth Factor AVEGFA protein, humanHeparin sulfatePhage displayVascular endothelial growth factorVEGFVEGF-Cell binding assayVEGF isoforms

Identifiers

PMID38954982
PMCPMC11298814

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.